Home/Pipeline/Oncology Portfolio

Oncology Portfolio

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Third Arc Bio

About Third Arc Bio

Third Arc Bio is a private, preclinical-stage biotech pioneering a new class of multifunctional antibody therapeutics, which it terms the 'Third Arc' of biologics. The company's platform is designed to engineer optimized biologics that engage multiple targets and cell types by leveraging immune synapse biology, aiming to overcome limitations in treating solid tumors and autoimmune diseases. Led by a seasoned team with a collective history of over 35 drug approvals, the company is backed by venture capital and is actively building its pipeline. Its recent Series A extension provides capital to grow its oncology and I&I portfolios.

View full company profile

Therapeutic Areas

Oncology Immunology & Inflammation

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed